NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal
Publication Date
2026
Content Type
article
PubMed ID:
Citation
Journal of Clinical Oncology (2026) 44(6):497-507